HCM
UTHR icon

Highbridge Capital Management’s United Therapeutics UTHR Stock Holding History

Highbridge Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9,200
Closed -$1.36M – 1744
2017
Q4 		$1.36M Buy
+9,200
New +$1.17M 0.02% 470

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Highbridge Capital Management's UTHR Position: Q4 2016 in Review

Highbridge Capital Management sold out of United Therapeutics (UTHR) in Q4 2016, closing a stake of 91,698 shares — an estimated $10.8M sold.

Highbridge Capital Management first reported a position in UTHR in Q2 2013 and held it in 9 quarters. The position peaked at $10.8M in Q3 2016. 406 funds tracked by Wall St. Rank hold UTHR as of Q4 2016.

  • Highbridge Capital Management reported no remaining United Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 91,698 United Therapeutics shares in Q4 2016, an estimated $10.8M.
  • Highbridge Capital Management first reported a position in United Therapeutics in Q2 2013 and held it in 9 quarters.
  • Highbridge Capital Management's United Therapeutics position peaked at $10.8M in Q3 2016.
  • 406 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.